Ayta, Danneza Mae P.

HRN: 27-64-59  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/18/2025
CO-AMOXICLAV 625MG (TAB)
08/18/2025
08/25/2025
ORAL
625mg
BID
S/P NSD With Repair; PROM
Checking Initial Appropriateness 

 Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines